Syngene International Limited has informed the Exchange regarding a press release dated July 23, 2025, titled "First quarter revenue from operations up 11% year-on-year to Rs. 875 Cr".
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Smallcap 250 and 1.6 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene International reported Q1 FY26 revenue from operations of Rs. 875 Cr, up 11% year-on-year from Rs. 790 Cr in Q1 FY25. Reported EBITDA grew 19% to Rs. 224 Cr, with EBITDA margin expanding by about 200 basis points to 25%. Profit after tax (before exceptional items) jumped 59% to Rs. 87 Cr, with PAT margin improving to 10% from 7%, partly aided by a tax benefit from transfer of gratuity funds to an Employee Gratuity Trust. The company highlighted strong growth in Research Services driven by conversion of pilot programs into long-term contracts, and progress at its new Biologics Unit III facility in Bengaluru, with the U.S. Bayview facility expected to start operations later this year. The company reaffirmed its full-year guidance and noted a clean USFDA inspection of its Human Pharmacology Unit with no observations.
Positive quarter with broad-based growth across revenue, margins, and profits signals strong operational momentum and likely supports the stock. Margin expansion and reaffirmed FY26 guidance are key positives for shareholders.